secwatch.observer — SEC 8-K summary
======================================

Issuer:     MiNK Therapeutics, Inc. (INKT)
CIK:        0001840229
Form:       8-K
Filed at:   2025-03-18T23:59:59+00:00
Accession:  0001171843-25-001513
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MiNK Therapeutics reports FY2024 net loss of $10.8M, improved from $22.5M in 2023
--------------------------------------------------------------------------------

- Net loss for FY2024 was $10.8M ($2.86/diluted share) vs $22.5M ($6.54/share) in 2023.
- Cash and cash equivalents at Dec 31, 2024 were $4.6M, up from $3.4M at year-end 2023.
- Cash used in operations for FY2024 was $9.6M, compared to $15.8M in 2023.
- Clinical progress: AgenT-797 Phase 2 gastric cancer trial enrolling; ARDS data showed ~80% survival in VV ECMO patients.
- Raised $5.8M in private financing in 2024; collaboration with Autonomous Therapeutics for RNA-iNKT therapies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840229/000117184325001513/0001171843-25-001513-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840229/000117184325001513/f8k_031825.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-001513

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer